- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Annual CT scan detects early-stage lung cancer
A 10-year study has determined that annual CT scans could prevent as many as half of lung cancer deaths. Annual screening detects early-stage lung cancers, which have a curability rate of 80% to 90%.
A 10-year study has determined that annual CT scans could prevent as many as half of lung cancer deaths. Annual screening detects early-stage lung cancers, which have a curability rate of 80% to 90%.
"More than 80% of the diagnosed lung cancer we found in initial and annual repeat CT screenings were stage I, the most curable form of lung cancer," said Dr. Claudia I. Henschke, principal investigator and division chief of chest imaging at New York Hospital-Cornell Medical Center.
An international study of 2968 high-risk patients conducted by the Early Lung Cancer Action Project found that annual screens are most likely to catch lung cancer at its earliest stages. Lung cancer symptoms often do not appear until the cancer has advanced to stage II or III.
The ELCAP study found that people with part-solid lung nodules were 19 times more likely to develop cancer than those with completely solid nodules. In addition, at-risk women are 2.2 times more likely to develop cancer than at-risk men.
"There is, as of yet, no clear consensus why women are at increased risk," Henschke said.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
